TY - JOUR
T1 - Effects of androgen modifying therapies on disease activity in older men with multiple sclerosis
AU - Zeydan, Burcu
AU - Neyal, Nur
AU - Nathoo, Nabeela
AU - Rangachari, Manu
AU - Atkinson, Elizabeth J.
AU - Son, Jiye
AU - Conway, Brittani L.
AU - Tobin, W. Oliver
AU - Keegan, B. Mark
AU - Weinshenker, Brian G.
AU - Kantarci, Kejal
AU - Oh, Jiwon
AU - Kantarci, Orhun H.
N1 - Publisher Copyright:
© 2025 Elsevier B.V.
PY - 2025/6/15
Y1 - 2025/6/15
N2 - Background: Anti-inflammatory properties of androgens were assessed in animal models, but only several clinical studies investigated the effects of androgen on multiple sclerosis (MS). Inflammatory activity in MS often attenuates with aging, and androgen modifying therapies (AMT), which mimic decreased androgen levels, are frequently used in older men. We aimed to investigate if the number of disease activity events would increase in older (≥55 years) male persons with MS (MPwMS) who are on AMT. Methods: MPwMS with AMT initiation ≥55 years (AMT; n = 60) and without AMT history (no-AMT; n = 80) were included from a clinical-based observational study cohort. Clinical (relapses), Radiological (new lesions), and Disease (relapses and/or new lesions) activity events were evaluated before and after the age at AMT initiation in AMT and no-AMT groups. Results: Age at MS onset, progressive MS rate and treatment frequencies were similar between the groups. When events before and after the age at AMT initiation (mean = 65.0 ± 7.0 years) were compared, there was a drop in the percentage of individuals with Clinical (38.5 % vs. 10 %), Radiological (46.2 % vs. 40 %) and Disease (62.8 % vs. 40 %) activity events in the no-AMT group. In the AMT group, the percentage of individuals with Clinical activity events was not as dramatically decreased (33.3 % vs. 22.2 %), Radiological activity events was increased (35.2 % vs. 46.7 %), and Disease activity events was sustained (51.9 % vs. 51.1 %). The probability of Disease activity was higher in the AMT group at 3 years of AMT initiation (40 % vs. 29 %) compared to the no-AMT group matched for disease duration, but the difference was not significant (p = 0.582). Conclusions: Rather than the expected decrease in disease activity with age, MPwMS receiving AMT experienced sustained or increased disease activity, particularly at >65 years. Close clinical monitoring of MPwMS starting on these medications is necessary.
AB - Background: Anti-inflammatory properties of androgens were assessed in animal models, but only several clinical studies investigated the effects of androgen on multiple sclerosis (MS). Inflammatory activity in MS often attenuates with aging, and androgen modifying therapies (AMT), which mimic decreased androgen levels, are frequently used in older men. We aimed to investigate if the number of disease activity events would increase in older (≥55 years) male persons with MS (MPwMS) who are on AMT. Methods: MPwMS with AMT initiation ≥55 years (AMT; n = 60) and without AMT history (no-AMT; n = 80) were included from a clinical-based observational study cohort. Clinical (relapses), Radiological (new lesions), and Disease (relapses and/or new lesions) activity events were evaluated before and after the age at AMT initiation in AMT and no-AMT groups. Results: Age at MS onset, progressive MS rate and treatment frequencies were similar between the groups. When events before and after the age at AMT initiation (mean = 65.0 ± 7.0 years) were compared, there was a drop in the percentage of individuals with Clinical (38.5 % vs. 10 %), Radiological (46.2 % vs. 40 %) and Disease (62.8 % vs. 40 %) activity events in the no-AMT group. In the AMT group, the percentage of individuals with Clinical activity events was not as dramatically decreased (33.3 % vs. 22.2 %), Radiological activity events was increased (35.2 % vs. 46.7 %), and Disease activity events was sustained (51.9 % vs. 51.1 %). The probability of Disease activity was higher in the AMT group at 3 years of AMT initiation (40 % vs. 29 %) compared to the no-AMT group matched for disease duration, but the difference was not significant (p = 0.582). Conclusions: Rather than the expected decrease in disease activity with age, MPwMS receiving AMT experienced sustained or increased disease activity, particularly at >65 years. Close clinical monitoring of MPwMS starting on these medications is necessary.
KW - 5α-reductase inhibitors
KW - Age
KW - Androgen
KW - Disease activity
KW - Men
KW - Multiple sclerosis
KW - Sex differences
UR - http://www.scopus.com/inward/record.url?scp=105000640908&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105000640908&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2025.578589
DO - 10.1016/j.jneuroim.2025.578589
M3 - Article
AN - SCOPUS:105000640908
SN - 0165-5728
VL - 403
JO - Journal of neuroimmunology
JF - Journal of neuroimmunology
M1 - 578589
ER -